Most analyst forecasts do not factor into their Gilead valuations Yeztugo's share gains in the growing HIV prophylaxis market ...

Gilead Sciences ( ($GILD) ) has risen by 7.31%. Read on to learn why. Gilead Sciences has seen a notable increase in its ...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for ...

Gilead Sciences (GILD) stock gains as Needham upgrades the company to Buy from Hold citing its new HIV prevention injectable, ...

Similarly, Gilead has provided nearly $35.8 million in total philanthropic support for Black women-led and/or Black ...

Four months after giving Eli Lilly’s Alzheimer’s disease treatment a thumbs-down, Europe’s Committee for Medicinal Products ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the Best Large Cap Value Stocks to Invest In. Analyst Courtney Breen of ...

In June 1981, news of a mysterious disease first began making headlines out of San Francisco, Los Angeles and New York. People who were impacted developed unusual infections and grew sick as their ...

Gilead on Friday said the recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use covers lenacapavir for use as pre-exposure prophylaxis, or PrEP, to reduce ...

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...

Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. The company rose to ...

Gilead Sciences (GILD) stock slips as the company agrees to pay $202M to settle allegations that its HIV drug promotion ...